Probiotec Shareholders Approve Acquisition Deal

Probiotec Limited (AU:PBP) has released an update.

Shareholders of Probiotec Limited have overwhelmingly approved the acquisition of the company by PYFA Australia Pty Ltd, a subsidiary of Pyfa Health Singapore Pte Ltd, with over 92% of voting participants supporting the scheme. The arrangement is pending a final court approval and other conditions, expected to be completed by mid-June 2024, after which the company will suspend trading on the ASX. This move marks a significant transition for Probiotec, a prominent manufacturer and distributor of pharmaceutical and health products.

For further insights into AU:PBP stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.